Key regions: Australia, Brazil, United Kingdom, Europe, Canada
The Other Vaccines market in Central America is experiencing significant growth in recent years.
Customer preferences: Central American consumers are increasingly prioritizing preventative healthcare measures, including vaccinations, due to rising awareness of the benefits of disease prevention. Additionally, the COVID-19 pandemic has led to increased focus on healthcare and vaccine development, further driving demand for vaccines.
Trends in the market: In Central America, there is a growing trend of governments implementing vaccination programs for preventable diseases, such as HPV and meningitis. This has led to increased demand for Other Vaccines in the region. Furthermore, there is a growing trend of medical tourism in Central America, with many individuals traveling to the region for medical procedures, including vaccinations.
Local special circumstances: Central America is a region with significant economic and social disparities. While some countries in the region, such as Costa Rica and Panama, have relatively strong healthcare systems and high vaccination rates, other countries, such as Honduras and Nicaragua, have weaker healthcare systems and lower vaccination rates. This has led to a greater need for preventative healthcare measures, including vaccinations, in countries with weaker healthcare systems.
Underlying macroeconomic factors: One of the key macroeconomic factors driving the growth of the Other Vaccines market in Central America is the region's growing middle class. As more individuals in the region move into the middle class, they are increasingly able to afford preventative healthcare measures, including vaccinations. Additionally, the region's growing population, particularly in urban areas, is driving demand for healthcare services, including vaccinations. Finally, the COVID-19 pandemic has highlighted the importance of preventative healthcare measures, further driving demand for vaccinations in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
